94
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK

, , &
Pages 805-815 | Accepted 16 Feb 2005, Published online: 25 Apr 2005

References

  • Souhami R, Tobias J, editors. Breast cancer. In: Cancer and its management. Oxford: Blackwell Science; 1998. pp. 216–34
  • Paterson AHS. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer 2000;88:3038–46
  • The Breast Specialty Group of the British Association of Surgical Oncology. British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom. Eur J Surg Oncol 1999;25:3–23
  • Lacerna L, Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumours. Seminars in Oncology 2003;30(5 Suppl 16):150–60
  • Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. The Cancer Journal 2001;7(5):377–87
  • Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technology Assessment 2004;8(4)
  • Pavlakis N, Stockler M. Bisphosphonates for breast cancer (Cochrane review). The Cochrane Library, vol. 4. Chichester, UK: John Wiley & Sons, Ltd; 2003
  • Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [Myeloma Aredia Study Group]. NEJM 1996;334(8):488–93
  • Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [Myeloma Aredia Study Group]. J Clin Oncol 1998;16(2):593–602
  • Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate [Protocol 19 Aredia Breast Cancer Study Group]. J Clin Oncol 1998;16(6):2038–44
  • Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases [Protocol 19 Aredia Breast Cancer Study Group]. NEJM 1996;335(24):1785–91
  • Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is an effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88(5):1082–90
  • NHS Executive Reference Costs 2003. Leeds: Department of Health 2003
  • BNF (British National Formulary). London: BMA and Royal Pharmaceutical Society of Great Britain, 2004
  • Datamonitor. Treatment algorithms 2001: Breast cancer. Reference Code: DMHC1683. 2001. Datamonitor, London
  • Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia; WB Saunders Co.; 1980. pp. 228–65
  • Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003;98(8): 1735–43
  • Romanus D, Iscoe N, DeAngelis C, et al. Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients. Supportive Care in Cancer 2004 [published on line]
  • DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care in Cancer 2001;9:545–51

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.